Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Low-Dose Decitabine Combined with Modified Bucy Is More Effective Conditioning Regimen for High-Risk Patients with Acute Myeloid Leukaemia/Myelodysplastic Syndrome

Xiaowen Tang, MD, Jing Cao, Xiaojing Shi, Ling Ge, Aining Sun, PhD, Xiaming Zhu, Huiying Qiu, Zhengming Jin, Miao Miao, Chengcheng Fu, Xiao Ma, Feng Chen, Shengli Xue, Yue Han, MD, Mengxing Xue, Xinliang Mao, PhD, Depei Wu, MD PhD

Blood (2016) 128 (22): 5750.

https://doi.org/10.1182/blood.V128.22.5750.5750

Published: 2016

Journal Articles

A Novel PI3K Inhibitor Identified By a High Throughput Virtual Screen Displays Potent Activity Against Multiple Myeloma

Biyin Cao, MD PhD, Jingyu Zhu, PhD, Man Wang, Yang Yu, Huixin Qi, Kunkun Han, Zubin Zhang, Yuanying Zeng, MD, Chunhua Qiao, PhD, Hongjian Zhang, PhD, Tingjun Hou, PhD, Xinliang Mao, PhD

Blood (2014) 124 (21): 4722.

https://doi.org/10.1182/blood.V124.21.4722.4722

Published: 2014

Journal Articles

A Novel Non-Competitive Chemical Proteasome Inhibitor Displays Preclinical Activity in Myeloma and Leukemia.

Xiaoming Li, PhD, Tabitha E Wood, PhD, Remco Sprangers, PhD, Xinliang Mao, PhD, Xiaoming Wang, PhD, Yi Zhang, BSc, David Rose, PhD, Robert A. Batey, PhD, Lewis E. Kay, PhD, Aaron D. Schimmer, MD, PhD

Blood (2008) 112 (11): 1711.

https://doi.org/10.1182/blood.V112.11.1711.1711

Published: 2008

Journal Articles

The Oral Off-Patent Antimicrobial Clioquinol Inhibits the Proteasome and Induces Cell Death in AML and Myeloma Cells through a Copper-Dependent Mechanism.

Xinliang Mao, PhD, Xiaoming Li, PhD, Rose Hurren, Bsc, Amudha Venugopal, PhD, Suzanne Trudel, MD, A. Keith Stewart, MD, Aaron D. Schimmer, MD, PHD

Blood (2007) 110 (11): 1595.

https://doi.org/10.1182/blood.V110.11.1595.1595

Published: 2007

Journal Articles

A High Throughput Screen Identified Cyproheptadine That Decreases D-Type Cyclins, Arrests Cells in the G1 Phase, and Induces Apoptosis in Multiple Myeloma and Leukemia Cells.

Xinliang Mao, PhD, A. Keith Stewart, MD, Rose Hurren, BSc, Marcela Gronda, MSc, Kyle Lee, BSc, Sue Chow, BSc, Shengben Liang, PhD, Suzanne Trudel, MD, David W. Hedley, MD, PhD, Aaron D. Schimmer, Md, PhD

Blood (2007) 110 (11): 1507.

https://doi.org/10.1182/blood.V110.11.1507.1507

Published: 2007

Journal Articles

Chemical Library Screening Identifies Novel Inhibitors of Cyclin D2 ( CCND2) Transactivation That Selectively Induce Apoptosis in Multiple Myeloma Cells.

Rodger E. Tiedemann, MD, PhD, Xinliang Mao, PhD, Chng-Xin Shi, PhD, Yuan Xiao Zhang, PhD, Stephen Palmer, Craig B. Reeder, MD, Aaron Schimmer, MD, Keith Stewart, MD

Blood (2006) 108 (11): 3421.

https://doi.org/10.1182/blood.V108.11.3421.3421

Published: 2006

Journal Articles

Kinetin Riboside Is a Novel Targeted Inhibitor of CCND1 and CCND2 Transactivation with Substantial Preclinical Anti-Myeloma Activity.

Rodger E. Tiedemann, MD, PhD, Xinliang Mao, PhD, Ronald J. Marler, DVM, PhD, Craig B. Reeder, MD, Aaron Schimmer, MD, Keith Stewart, MD

Blood (2006) 108 (11): 367.

https://doi.org/10.1182/blood.V108.11.367.367

Published: 2006

NARROW

Low-Dose Decitabine Combined with Modified Bucy Is More Effective Conditioning Regimen for High-Risk Patients with Acute Myeloid Leukaemia/Myelodysplastic Syndrome

A Novel PI3K Inhibitor Identified By a High Throughput Virtual Screen Displays Potent Activity Against Multiple Myeloma

A Novel Non-Competitive Chemical Proteasome Inhibitor Displays Preclinical Activity in Myeloma and Leukemia.

The Oral Off-Patent Antimicrobial Clioquinol Inhibits the Proteasome and Induces Cell Death in AML and Myeloma Cells through a Copper-Dependent Mechanism.

A High Throughput Screen Identified Cyproheptadine That Decreases D-Type Cyclins, Arrests Cells in the G1 Phase, and Induces Apoptosis in Multiple Myeloma and Leukemia Cells.

Chemical Library Screening Identifies Novel Inhibitors of Cyclin D2 ( CCND2) Transactivation That Selectively Induce Apoptosis in Multiple Myeloma Cells.

Kinetin Riboside Is a Novel Targeted Inhibitor of CCND1 and CCND2 Transactivation with Substantial Preclinical Anti-Myeloma Activity.

Email alerts

ASH Publications

American Society of Hematology

Low-Dose Decitabine Combined with Modified Bucy Is More Effective Conditioning Regimen for High-Risk Patients with Acute Myeloid Leukaemia/Myelodysplastic Syndrome

A Novel PI3K Inhibitor Identified By a High Throughput Virtual Screen Displays Potent Activity Against Multiple Myeloma

A Novel Non-Competitive Chemical Proteasome Inhibitor Displays Preclinical Activity in Myeloma and Leukemia.

The Oral Off-Patent Antimicrobial Clioquinol Inhibits the Proteasome and Induces Cell Death in AML and Myeloma Cells through a Copper-Dependent Mechanism.

A High Throughput Screen Identified Cyproheptadine That Decreases D-Type Cyclins, Arrests Cells in the G1 Phase, and Induces Apoptosis in Multiple Myeloma and Leukemia Cells.

Chemical Library Screening Identifies Novel Inhibitors of Cyclin D2 ( CCND2) Transactivation That Selectively Induce Apoptosis in Multiple Myeloma Cells.

Kinetin Riboside Is a Novel Targeted Inhibitor of CCND1 and CCND2 Transactivation with Substantial Preclinical Anti-Myeloma Activity.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only